Bubuka Dina domain onkologi, immunotherapy geus mecenghul salaku metodologi pioneering, harnessing sistim imun awak pikeun merangan tumor ganas. Aya seueur pendekatan immunotherapeutic, tapi Chimeric Antigen Rece..
Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or refractory (r/r) B-cell precurs..
Oktober 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) parantos disatujuan ku Administrasi Pangan sareng Narkoba pikeun penderita sawawa anu kambuh atanapi refractory prékursor sél B leukemia limfoblastik akut (ALL). Di..
Juli 2021: Pariksa ubar panganyarna dina pengobatan kanker. Unggal taun, saatos nguji uji coba sareng faktor penting anu sanés, USFDA nyatujuan ubar, sahingga penderita kanker ayeuna tiasa percanten yén ubarna caket pisan. ..